EUVIMEDEUVIMED entdecken
Klinische StudieMultizentrische StudieOpen Access · CC BY 4.0

Five-year results from a prospective, single-arm European trial on decellularized allografts for aortic valve replacement—the ARISE Study and ARISE Registry Data

Alexander Horke iD, Igor Tudorache, Günther Laufer, Martin Andreas iD, Jose Luis Pomar, Daniel Pereda iD, Eduard Quintana, Marta Sitges iD, Bart Meyns iD, Filip Rega iD, Mark Hazekamp, Robert Cesnjevar und 13 weitere

European Journal of Cardio-Thoracic Surgery · 2024

DOI: 10.1093/ejcts/ezae121 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift European Journal of Cardio-Thoracic Surgery, 2024. Verfasst von Alexander Horke und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department for Cardiothoracic, Transplant, and Vascular Surgery, Hannover Medical School, Hannover, Germany. Hauptthemen laut MEDLINE: Aortic Valve Insufficiency, Aortic Valve Stenosis, Endocarditis, Heart Valve Prosthesis. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union's HORIZON 2020, European Union’s HORIZON 2020.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES Decellularized aortic homografts (DAH) were introduced as a new option for aortic valve replacement for young patients. METHODS A prospective, EU-funded, single-arm, multicentre study in 8 centres evaluating non-cryopreserved DAH for aortic valve replacement. RESULTS A total of 144 patients (99 male) were prospectively enrolled in the ARISE Trial between October 2015 and October 2018 with a median age of 30.4 years [interquartile range (IQR) 15.9–55.1]; 45% had undergone previous cardiac operations, with 19% having 2 or more previous procedures. The mean implanted DAH diameter was 22.6 mm (standard deviation 2.4). The median operation duration was 312 min (IQR 234–417), the median cardiopulmonary bypass time was 154 min (IQR 118–212) and the median cross-clamp time 121 min (IQR 93–150). No postoperative bypass grafting or renal replacement therapy were required. Two early deaths occurred, 1 due to a LCA thrombus on day 3 and 1 due ventricular arrhythmia 5 h postoperation. There were 3 late deaths, 1 death due to endocarditis 4 months postoperatively and 2 unrelated deaths after 5 and 7 years due to cancer and Morbus Wegener resulting in a total mortality of 3.47%. After a median follow-up of 5.9 years [IQR 5.1–6.4, mean 5.5 years. (standard deviation 1.3) max. 7.6 years], the primary efficacy end-points peak gradient with median 11.0 mmHg (IQR 7.8–17.6) and regurgitation of median 0.5 (IQR 0–0.5) of grade 0–3 were excellent. At 5 years, freedom from death/reoperation/endocarditis/bleeding/thromboembolism were 97.9%/93.5%/96.4%/99.2%/99.3%, respectively. CONCLUSIONS The 5-year results of the prospective multicentre ARISE trial continue to show DAH to be safe for aortic valve replacement with excellent haemodynamics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Aortic Valve InsufficiencyAortic Valve StenosisEndocarditisHeart Valve ProsthesisHeart Valve Prosthesis ImplantationAdultHumansMaleAllograftsAortic ValveFollow-Up StudiesProspective StudiesReoperationRoutinely Collected Health DataFemaleAdolescentYoung AdultMiddle Aged

Stichwörter der Autor:innen

AllograftsAortic valve diseaseDecellularizationTissue engineering

Autor:innen und Institutionen

  • Department for Cardiothoracic, Transplant, and Vascular Surgery, Hannover Medical School, Hannover, Germany.
  • Clinic for Cardiac Surgery, University Heart Center Zurich, Zurich, Switzerland.
  • Department of Cardiac Surgery, Medical University of Vienna, Vienna, Austria.
  • Department of Cardiovascular Surgery, Hospital Clinico de Barcelona, Barcelona, Spain.
  • Department of Cardiology, Hospital Clinico de Barcelona, Barcelona, Spain.
  • Department of Cardiac Surgery, Katholieke Universiteit Leuven, Leuven, Belgium.

ORCID-Profile: Alexander Horke, Martin Andreas, Daniel Pereda, Marta Sitges, Bart Meyns, Filip Rega, Artur Lichtenberg, Samir Sarikouch

Förderung

  • European Union's HORIZON 2020
  • European Union’s HORIZON 2020

Zitieren

APA

Horke, A., Tudorache, I., Laufer, G., Andreas, M., Pomar, J. L., Pereda, D., Quintana, E., Sitges, M., Meyns, B., Rega, F., Hazekamp, M., Cesnjevar, R., Schmiady, M. O., Pepper, J., Rosendahl, U., Lichtenberg, A., Stadnik, D., Jashari, R., Boethig, D., …, & Sarikouch, S. (2024). Five-year results from a prospective, single-arm European trial on decellularized allografts for aortic valve replacement—the ARISE Study and ARISE Registry Data. European Journal of Cardio-Thoracic Surgery. https://doi.org/10.1093/ejcts/ezae121

Vancouver

Horke A, Tudorache I, Laufer G, Andreas M, Pomar JL, Pereda D, et al. Five-year results from a prospective, single-arm European trial on decellularized allografts for aortic valve replacement—the ARISE Study and ARISE Registry Data. European Journal of Cardio-Thoracic Surgery. 2024. doi:10.1093/ejcts/ezae121

BibTeX
@article{Horke2024,
  author = {Horke, Alexander and Tudorache, Igor and Laufer, Günther and Andreas, Martin and Pomar, Jose Luis and Pereda, Daniel and Quintana, Eduard and Sitges, Marta and Meyns, Bart and Rega, Filip and Hazekamp, Mark and Cesnjevar, Robert and Schmiady, Martin Oliver and Pepper, John and Rosendahl, Ulrich and Lichtenberg, Artur and Stadnik, Dmytro and Jashari, Ramadan and Boethig, Dietmar and Bobylev, Dmitry and Avsar, Murat and Ruhparwar, Arjang and Haverich, Axel and Cebotari, Serghei and Sarikouch, Samir},
  title = {Five-year results from a prospective, single-arm European trial on decellularized allografts for aortic valve replacement—the ARISE Study and ARISE Registry Data},
  journal = {European Journal of Cardio-Thoracic Surgery},
  year = {2024},
  doi = {10.1093/ejcts/ezae121}
}
Kostenlos starten →